Premium
Myelin basic protein and creatine kinase BB isoenzyme as CSF markers of intracranial tumors and stroke
Author(s) -
MatiasGuiu J.,
MartinezVazquez J.,
Ruibal A.,
Colomer R.,
Boada M.,
Codina A.
Publication year - 1986
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1986.tb04585.x
Subject(s) - creatine kinase , medicine , myelin basic protein , isozyme , stroke (engine) , pathology , myelin , biology , biochemistry , enzyme , central nervous system , mechanical engineering , engineering
In patients with intracranial tumors (ICT) and acute cerebral infarctions (CI), both necrosis and reversible changes occur in central nervous system (CNS) tissue. The damaged CNS cells release specific substances into the cerebrospinal fluid (CFS). Radioimmunoassay (RIA)‐determined myelin basic protein (MBP) and RIA‐determined creatin kinase BB (CK‐BB) are markers of damage to CNS specific structures. The elevated CSF level of MBP is considered a marker of myelin damage and the increased concentration of CSF CK‐BB may be of combined neuronal and astrocytic origin. CSF was collected from 57 patients with the diagnosis of CI ( n =30) and ICT ( n =27) and the concentration of MBP and CK‐BB were measured by RIA. Our study shows increased CSF levels of MBP and CK‐BB in patients with CI and patients with ICT. We have also found a linear correlation between MBP and CK‐BB in both CI and ICT, and for a given CK‐BB level, MBP was significantly higher in patients with ICT than in patients with CI. These facts suggest that lesion markers behave differently in the different pathologic processes affecting the CNS.